{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(6)"],"submitter":["Mazzucconi MG"],"pubmed_abstract":["<h4>Abstract</h4>A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP). An ad hoc study compared PDN with HD-DXM in newly diagnosed untreated patients with pITP (aged ≥18 but ≤80 years, platelet count of ≤20 or >20 but <50 × 109/L, and bleeding score of ≥8). Patients were randomised to receive PDN 1 mg/kg per day from days 0 to 28 (Arm A) or HD-DXM 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B). Fifty-nine of 113 patients (52.2%) were randomized to Arm A and 54 of 113 (47.8%) to Arm B. In evaluable patients, total initial responses (complete response [CR], partial response"],"journal":["Blood advances"],"pagination":["1529-1540"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10966179"],"repository":["biostudies-literature"],"pubmed_title":["Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial."],"pmcid":["PMC10966179"],"pubmed_authors":["Paoloni F","Ranalli P","Rossi E","Di Ianni M","Giuffrida AC","Crugnola M","Avvisati G","De Stefano V","Sibilla S","Martino B","Rivolti E","Palandri F","Patriarca A","Carella AM","Ruggeri M","Carli G","Battistini R","Siragusa S","Sargentini V","Lugli E","Gentile M","Gugliotta L","Fortuna S","Polverelli N","Musto P","Tafuri A","Santoro C","Vianelli N","Bocchia M","Rago A","Rodeghiero F","D'Adda M","Mazzucconi MG","Baldacci E","Ferretti A","Zaja F","Fazi P","Di Renzo N","Vincelli ID","Krampera M"],"additional_accession":[]},"is_claimable":false,"name":"Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.","description":"<h4>Abstract</h4>A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP). An ad hoc study compared PDN with HD-DXM in newly diagnosed untreated patients with pITP (aged ≥18 but ≤80 years, platelet count of ≤20 or >20 but <50 × 109/L, and bleeding score of ≥8). Patients were randomised to receive PDN 1 mg/kg per day from days 0 to 28 (Arm A) or HD-DXM 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B). Fifty-nine of 113 patients (52.2%) were randomized to Arm A and 54 of 113 (47.8%) to Arm B. In evaluable patients, total initial responses (complete response [CR], partial response","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-21T21:28:14.113Z","creation":"2025-04-05T18:25:46.363Z"},"accession":"S-EPMC10966179","cross_references":{"pubmed":["38231017"],"doi":["10.1182/bloodadvances.2023010975"]}}